ClinicalTrials.gg
RecruitingNCT07737314Updated Nov 6, 2026

Tele-HOPE: A Telehealth Pharmacist Opioid Patient Education Pilot Study

An interventional study of Survey Administration and Electronic Health Record Review in Hematopoietic and Lymphatic System Neoplasm and Malignant Solid Neoplasm, sponsored by Fred Hutchinson Cancer Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Fred Hutchinson Cancer Center · Not applicable, Interventional, and Supportive care

How we know

Updated Nov 6, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This clinical trial will evaluate the feasibility, acceptability, and potential efficacy of a palliative care pharmacist-led group telehealth opioid education session for palliative care patients prescribed opioids for cancer-related pain. While opioids are commonly used in palliative care settings to manage cancer-related pain, their significant side effects, complicated administration requirements, and concerns about addiction can make it challenging for patients to use opioids safely and effectively. Some patients may even avoid opioids altogether because of these concerns, even when opioids are clinically indicated, leading to poor symptom control. To address these challenges, a telehealth education session was developed as a clinical initiative by a palliative care pharmacist, addressing safe and effective opioid management. Educational priorities and session content were informed by a survey of interdisciplinary palliative care clinicians that identified barriers and facilitators to opioid education and key patient educational needs. Patients scheduled to attend a pharmacist-led group telehealth opioid education session who enroll in the study will complete a survey before the session and another survey afterward. This study will assess the feasibility and acceptability of delivering the intervention, as well as its preliminary effects on opioid knowledge and self-efficacy. If feasible and acceptable, this pharmacist-led telehealth education model could represent a scalable strategy to improve opioid management for patients with cancer-related pain.

Read the detailed description

OUTLINE:

Patients scheduled to attend a pharmacist-led group telehealth opioid education session who enroll in the study will complete a survey before the session and another survey afterward. After attending the pharmacist education session, patients will receive a patient education handout summarizing the educational content.

After attending the pharmacist education session, participants will complete the final survey within 1 month, concluding their participation.

02

Conditions studied

  • Hematopoietic and Lymphatic System Neoplasm
  • Malignant Solid Neoplasm
03

In context

Lead sponsor

Fred Hutchinson Cancer Center is the lead sponsor of 547 studies on the registry; 79 are open to participants now.

Of its 59 completed or terminated interventional studies of FDA-regulated products, 46 (78%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years, consistent with the population of patients treated at Fred Hutch Cancer Center
  • A cancer diagnosis
  • Established care in the Fred Hutch Palliative Care Clinic (≥ 1 visit with a Fred Hutch palliative care physician or advanced practice provider within the past 12 months)
  • Prescribed opioids, defined as either ≥ 1 opioid prescription within the past 6 months documented in the Washington Prescription Drug Monitoring Program (PDMP), or a new opioid prescription initiated by the referring palliative care provider at the time of referral
  • Ability to understand and willingness to agree to an electronic consent document
  • Enrolled in MyChart and ability to participate in a telehealth video visit

Exclusion criteria

Exclusion Criteria:

  • Patients who prefer a language other than English for healthcare, as the session will be conducted live and cannot currently be offered in other languages
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Supportive care (pharmacist-led opioid education session)

    Patients scheduled to attend a pharmacist-led group telehealth opioid education session who enroll in the study will complete a survey before the session and another survey afterward. After attending the pharmacist education session, patients will receive a patient education handout summarizing the educational content.

    Other: Survey Administration · Other: Electronic Health Record Review

Interventions

  • OtherSurvey Administration

    Ancillary studies - pre- and post-session surveys to assess opioid knowledge and self-efficacy, and post-session to assess session acceptability

  • OtherElectronic Health Record Review

    Ancillary studies

06

What researchers measure

Primary outcomes

  1. Percentage of referred patients who attend pharmacist education session (Feasibility)

    Feasibility of the pharmacist education session will be interpreted as an overall session attendance-to-referral rate ≥ 50%.

    Time frame: Up to 6 months

  2. Participant score on the "general acceptability" item of the Theoretical Framework of Acceptability questionnaire

    Assessed on post-session surveys, delivered within 7 days after session attendance, with up to one month of follow-up to encourage survey completion. Acceptability of the pharmacist education session will be interpreted as \> 70% respondents rating the sessions as ≥ 4/5 (i.e. "acceptable" or "completely acceptable") on the "general acceptability" item of the Theoretical Framework of Acceptability scale (5 point Likert scale), assessed on the post-session survey.

    Time frame: Up to 1 month post-session

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — This study will generate quantitative and qualitative human subjects data as part of a pilot evaluation of a palliative care pharmacist-led group telehealth opioid education session intervention for patients with cancer pain. Quantitative data will include structured survey responses and electronic health record data. The shared data package will include de-identified quantitative datasets, qualitative data files where appropriate, data dictionaries/codebooks, and copies of study instruments, subject to instrument licensing requirements. De-identified datasets will be preserved and shared via a suitable repository that supports health-related research data, such as a general-purpose repository (e.g., Dryad or Figshare) or an institutional repository supported by Fred Hutchinson Cancer Center. The selected repository will provide persistent identifiers (e.g., DOIs) to support citation and long-term access.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Data will be made available no later than the time of publication of the primary study results or within 12 months of completion of the project period, whichever occurs first.

Access criteria: Shared data will be made available with minimal access restrictions, consistent with protecting participant privacy and honoring informed consent. Data will be licensed to permit reuse for non-commercial research purposes, including secondary analyses, methodologic studies, and meta-analyses, with appropriate citation of the original dataset and investigators. Users of the data will be required to acknowledge the data source in publications and presentations. No attempt will be made to re-identify study participants, and no data will be shared that could reasonably place participants at risk of deductive disclosure.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2026 (actual). Primary completion is estimated for Jul 2027, 8 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 27, 2026
First posted
Jul 30, 2026
StartActual
Nov 3, 2026
Primary completionEst.
Jul 31, 2027
CompletionEst.
Aug 31, 2027
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 6, 2026
Sites
Fred Hutch/University of Washington Cancer Consortium is now Recruiting
Nov 6, 2026
Start date
Nov 1, 2026→Nov 3, 2026 (actual)
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Not yet recruiting→Recruiting
    Fred Hutch/University of Washington Cancer Consortium is now Recruiting
    Start date Nov 1, 2026→Nov 3, 2026 (now actual)

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07737314
Responsible party
Sponsor
First posted
Jul 30, 2026
Start date
Nov 3, 2026
Primary completion
Jul 31, 2027 (estimated)
Completion
Aug 31, 2027 (estimated)
Last update
Nov 6, 2026

Study contacts

Sheri Ballard
Contact
sballard@fredhutch.org
206-667-4222
Nicole Dussault, MD, MS
principal investigator · Fred Hutch/University of Washington Cancer Consortium

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion